Outcome measures for early phase clinical trials
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Amyotrophic Lateral Sclerosis
- Vol. 8 (5), 270-273
- https://doi.org/10.1080/17482960701547958
Abstract
As the number of potential neuroprotective agents for ALS increases, the need for early phase trials that screen drugs before proceeding to efficacy trials also grows. However, it is not known which outcome measures perform best and also provide the most meaningful information in brief small trials. We assessed the performance of different outcome measures for use in early phase clinical trials in ALS, and determined what degree of change in the ALSFRS‐R that patients could perceive. Thirty patients underwent six monthly ALS Functional Rating Scale (ALSFRS‐R), forced vital capacity, manual muscle testing (MMT) and quality of life assessments. Patients rated their perceived level of change with algorithm scales. Linear mixed effects models assessed the associations among variables and Cox proportional‐hazards models examined the ability to predict survival. The quantity of missing data was assessed using descriptive statistics. Correlations were found between all variables. The ALSFRS‐R provided the most complete data (99.5%), showed a large within‐subject correlation (0.91), and best predicted survival (p = 0.002). One‐unit change in patient‐perceived clinical function paralleled a 9‐point decrease in the ALSFRS‐R (p = 0.025; 95% CI ). This trial assessed just 30 patients over six months, but the standard outcome measures each performed dependably; all could be used in short‐duration, early phase trials. The ALSFRS‐R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects.Keywords
This publication has 10 references indexed in Scilit:
- Selecting promising ALS therapies in clinical trialsNeurology, 2006
- Development and evaluation of a self-administered version of the ALSFRS-RNeurology, 2006
- Randomized controlled phase II trial of glatiramer acetate in ALSNeurology, 2006
- A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSNeurology, 2006
- Pulmonary predictors of survival in amyotrophic lateral sclerosis: Use in clinical trial designMuscle & Nerve, 2005
- A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALSNeurology, 2005
- Rating the severity of ALS by caregivers over the telephone using the ALSFRS‐RAmyotrophic Lateral Sclerosis, 2005
- Respiratory muscle activity during REM sleep in patients with diaphragm paralysisNeurology, 2004
- A comparison of muscle strength testing techniques in amyotrophic lateral sclerosisNeurology, 2003
- Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) [RETIRED]Neurology, 1999